<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813043</url>
  </required_header>
  <id_info>
    <org_study_id>ANS0307</org_study_id>
    <nct_id>NCT03813043</nct_id>
  </id_info>
  <brief_title>The 90% Effective Sedation Dose Of Midazolam</brief_title>
  <official_title>Determination Of The 90% Effective Sedation Dose Of Midazolam In Patients Undergoing Diagnostic Upper Gastric-Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Fahad Specialist Hospital Dammam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Fahad Specialist Hospital Dammam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no clear conclusive clinical reports defining the adequate effective dose of&#xD;
      midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such&#xD;
      dosage will facilitate practitioners who are not anesthesia professionals to administer&#xD;
      sedative drugs to establish a satisfactory level of moderate sedation. Our first aim is to&#xD;
      determine the effective dose for 90% of patients (ED 90) of midazolam undergoing day-case&#xD;
      EGD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Midazolam is widely used in conscious sedation during esophageal-gastro-duodenoscopy (EGD) to&#xD;
      increase patient's tolerance and cooperation. Its short duration, cardiorespiratory&#xD;
      stability, anxiolytic and amnestic properties makes it the drug of choice for moderate&#xD;
      sedation in day case short procedure 1. Therefore, moderate sedation during digestive&#xD;
      endoscopy can be administered by endoscopist in safe monitored area while a qualified nurse&#xD;
      monitors the level of consciousness and vital sings. The endoscopist's privileges to&#xD;
      administer deeper alternative drug, i.e. propofol, might not be provided easily in many&#xD;
      centers especially outside the hospital due to certain limitations. However, the patient's&#xD;
      and endoscopist's satisfaction might not be achieved easily with the administration of&#xD;
      midazolam for moderate sedation. Inappropriate dose will fail to produce amnesia or may cause&#xD;
      respiratory side effect and delayed recovery and discharge. Therefore, there are no clear&#xD;
      conclusive clinical reports defining the adequate effective dose of midazolam in patients&#xD;
      undergoing day case EGD. This is obvious from different dosage used in various studies. In&#xD;
      addition, midazolam dosage in adult is rarely based on the body weight during our daily&#xD;
      clinical practice. Defining such dosage will facilitate practitioners who are not anesthesia&#xD;
      professionals to administer sedative drugs to establish satisfactory level of moderate&#xD;
      sedation. Our first aim is to determine the effective dose for 90% of patients (ED 90) of&#xD;
      midazolam undergoing day case EGD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 15, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Searching the ED90% of Midazolam using Biased coins method in 40 patients undergoing EGD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The result be found out at the end of the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Defining the ED90% of Midazolam for sedation of EGD</measure>
    <time_frame>10 months</time_frame>
    <description>Calculating the effective Midazolam sedative dosage in 90% of patients undergoing EGD</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastro-Esophageal Reflux Disease With Ulceration</condition>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Dormicum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1&amp;2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hypersensitivity to midazolam,&#xD;
&#xD;
          2. Age less than 18,&#xD;
&#xD;
          3. Obstructive sleep apnea&#xD;
&#xD;
          4. known or suspected memory impairment,&#xD;
&#xD;
          5. Patients with psychiatric disorders,&#xD;
&#xD;
          6. visual or hearing impairment and pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahed zeidan, MD</last_name>
    <role>Study Director</role>
    <affiliation>King Fahad Specialist Hospital Dammam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IRB IRB</last_name>
    <phone>+96613 844 2222</phone>
    <phone_ext>7093</phone_ext>
    <email>irb@kfsh.med.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Munir Bamadhaj, MD</last_name>
    <phone>+96613 844 2222</phone>
    <phone_ext>3993</phone_ext>
    <email>munir.bamdhaj@kfsh.med.sa</email>
  </overall_contact_backup>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Fahad Specialist Hospital Dammam</investigator_affiliation>
    <investigator_full_name>Munir Bamadhaj</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be collected inside the electronic system with limited access</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

